TL;DR: The Centers for Medicare & Medicaid Services modified NCD 223, the National Coverage Determination governing Medicare coverage of infusion pumps, effective March 7, 2026. Here's what billing teams need to know.
CMS updated NCD 223 to clarify and consolidate coverage criteria for both external and implantable infusion pumps across a range of indications — from continuous subcutaneous insulin infusion (CSII) to intrathecal drug delivery for cancer pain and spasticity. The policy does not list specific HCPCS or CPT codes in the current version, but it governs reimbursement for infusion pump devices and related drugs under the Durable Medical Equipment (DME) benefit category. If your practice or DME supplier bills Medicare for any pump-based drug delivery, this policy directly affects your coverage documentation requirements and your exposure to claim denial.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Infusion Pumps |
| Policy Code | NCD 223 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | High |
| Specialties Affected | Oncology, Endocrinology, Neurology, Pain Management, Hematology, Home Health / DME Suppliers |
| Key Action | Audit your medical necessity documentation for all active infusion pump patients against the updated criteria before March 7, 2026 |
CMS Infusion Pump Coverage Criteria and Medical Necessity Requirements 2026
NCD 223 is the National Coverage Determination governing Medicare coverage of infusion pumps — both external and implantable — as Durable Medical Equipment. The 2026 modification touches several distinct clinical indications, and the medical necessity bar for each is specific and non-negotiable. If your documentation doesn't match the criteria exactly, you're looking at a denial.
External Infusion Pumps
Medicare covers external infusion pumps for four primary indications, each with its own effective date and clinical conditions:
Iron Poisoning. External pumps are covered when used to administer deferoxamine for acute iron poisoning or iron overload. This is a narrow, well-defined indication — claims outside this drug-diagnosis pairing won't hold up.
Thromboembolic Disease. Heparin delivery via external infusion pump for thromboembolic disease or pulmonary embolism is covered, but only in an institutional setting. Home-based heparin pump claims under this indication are not covered under the current coverage policy.
Chemotherapy for Liver Cancer. The external chemotherapy infusion pump is covered for primary hepatocellular carcinoma or colorectal cancer when the disease is unresectable, or when the patient refuses surgical excision. Both conditions need to be documented explicitly — "unresectable" is a clinical determination that has to appear in the record, not just be implied.
Morphine for Intractable Cancer Pain. Morphine infusion via external pump is covered for intractable pain caused by cancer in any setting — inpatient, outpatient, or hospice. This is one of the broader indications in the policy and applies across care settings, which matters for billing teams working across multiple facility types.
Continuous Subcutaneous Insulin Infusion (CSII) Pumps
CSII is the most documentation-intensive indication in NCD 223, and it's where most claim denials happen. Coverage requires the patient to meet insulinopenia criteria — specifically, a fasting C-peptide level at or below 110% of the lower limit of normal for the lab's measurement method — OR be beta cell autoantibody positive.
Beyond the C-peptide or autoantibody requirement, patients must satisfy one of two pathway criteria:
Criterion A applies to new pump patients. The patient must have completed a comprehensive diabetes education program, been on multiple daily injections (at least three per day) with frequent self-adjustments for at least six months prior to pump initiation, and documented glucose self-testing at an average of at least four times per day during the two months before initiation. On top of that, at least one of the following must be documented: HbA1c above 7.0%, recurring hypoglycemia, wide pre-meal blood glucose fluctuations, dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dl, or a history of severe glycemic excursions.
Criterion B applies to Medicare new-enrollees already on a pump. The patient must have been using a pump prior to Medicare enrollment and must document glucose self-testing at an average of at least four times per day during the month before enrollment.
One detail that catches billing teams off guard: for patients with renal insufficiency and creatinine clearance at or below 50 ml/minute, the insulinopenia definition is modified. Don't apply the standard C-peptide threshold to these patients without confirming the renal-adjusted criteria.
The CSII section also extends to related drugs and supplies, which are covered as part of the same benefit when the pump itself is covered. Document everything together — pump, drug, and supplies — or you risk partial denial on the supply claims.
CMS Infusion Pump Exclusions and Non-Covered Indications
The coverage policy is explicit about where external pumps do and don't apply. Heparin delivery for thromboembolic disease is covered only in institutional settings — home use under this indication is not covered, and submitting those claims invites denial and potential overpayment scrutiny.
External pump coverage for liver cancer chemotherapy requires either unresectability or documented patient refusal of surgery. Pumps used outside these conditions — for resectable tumors where the patient hasn't declined surgery — fall outside covered indications.
For CSII, the most common non-coverage trigger is inadequate documentation of the six-month multiple daily injection regimen or glucose self-testing frequency. The criteria are quantitative. "The patient was on MDI" without dates, dosing frequency, and glucose log data is not sufficient.
Coverage Indications at a Glance
| Indication | Pump Type | Status | Key Requirement | Notes |
|---|---|---|---|---|
| Iron Poisoning (deferoxamine) | External | Covered | Acute iron poisoning or iron overload diagnosis | Deferoxamine must be the administered drug |
| Thromboembolic Disease / PE (heparin) | External | Covered | Institutional setting only | Home setting not covered under this indication |
| Primary Hepatocellular Carcinoma / Colorectal Cancer Chemotherapy | External | Covered | Disease unresectable OR patient refuses surgery | Document unresectability or refusal explicitly |
| Morphine for Intractable Cancer Pain | External | Covered | Intractable pain caused by cancer | Inpatient, outpatient, and hospice all covered |
| CSII — New Pump Patient (Criterion A) | External | Covered | ≥6 months MDI, ≥3 injections/day, ≥4 glucose tests/day (2 months prior), plus one glycemic criterion; C-peptide ≤110% LLN or autoantibody positive | Comprehensive diabetes education program required |
| CSII — Pre-Medicare Pump User (Criterion B) | External | Covered | Prior pump use + ≥4 glucose tests/day (month prior to enrollment); C-peptide ≤110% LLN or autoantibody positive | Applies to new Medicare enrollees already on CSII |
| CSII with Renal Insufficiency | External | Covered (modified criteria) | CrCl ≤50 ml/min triggers modified C-peptide threshold | Apply renal-adjusted insulinopenia definition |
CMS Infusion Pump Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit active CSII patient files before March 7, 2026. Pull every open CSII claim and pending authorization and confirm the file contains: C-peptide lab results with the lab's reference range, autoantibody results (if that's the qualifying pathway), documentation of six months of MDI with injection frequency, and two months of glucose logs showing at least four tests per day. Missing any one of these is a denial waiting to happen. |
| 2 | Check your renal patients against the modified C-peptide threshold. If you have CSII patients with creatinine clearance at or below 50 ml/minute, verify that the insulinopenia determination in the file used the renal-adjusted criteria, not the standard threshold. Correct any documentation that applied the wrong standard. |
| 3 | Confirm institutional setting documentation for heparin pump claims. For any external infusion pump claim submitted under the thromboembolic disease or pulmonary embolism indication, verify the claim reflects an institutional setting. Home-based administration under this indication is not covered — flag those claims for review before they go out. |
| 4 | Document unresectability or surgical refusal for liver cancer chemotherapy claims. Every external pump claim for hepatocellular carcinoma or colorectal cancer chemotherapy needs explicit documentation of either tumor unresectability or documented patient refusal of surgery. A treatment plan that doesn't state one of these two conditions doesn't meet coverage policy. |
| 5 | Update your DME supplier coordination workflows if you're billing related CSII supplies. CSII-related drugs and supplies are covered as part of the pump benefit, but only when the pump itself is covered. Make sure your charge capture links supply claims to the qualifying pump claim and that all supporting documentation travels together. |
| 6 | Loop in your compliance officer before March 7, 2026 if you have high CSII volume. The Criterion A documentation requirements are granular enough that even small documentation gaps create systematic denial exposure. If CSII makes up a meaningful share of your DME billing, have your compliance officer review a sample of recent files against the updated criteria now — not after the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Infusion Pumps Under NCD 223
The 2026 version of NCD 223 does not list specific CPT, HCPCS Level II, or ICD-10-CM codes in the policy document. This is not unusual for a foundational NCD — the specific billing codes for infusion pump devices, related supplies, and associated drugs are typically addressed in the applicable Local Coverage Determinations (LCDs) and the DME MAC fee schedules.
Your billing team should cross-reference NCD 223 coverage criteria with the relevant DME MAC LCD for infusion pumps in your jurisdiction. The DME MACs (CGS, Noridian, National Government Services, and Palmetto) maintain the specific HCPCS code lists and coverage articles that operationalize this NCD. If you're not sure which LCD applies to your claims, your DME MAC's website is the right starting point — or talk to your billing consultant before the March 7, 2026 effective date.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.